Login / Signup

No association of low-dose aspirin with severe COVID-19 in France: A cohort of 31.1 million people without cardiovascular disease.

Jérémie BottonLaura SemenzatoJulie DupouyRosemary Dray-SpiraAlain WeillOlivier Saint-LaryMahmoud Zureik
Published in: Research and practice in thrombosis and haemostasis (2022)
There was no evidence for an effect of low-dose aspirin for primary cardiovascular prevention in reducing severe COVID-19.
Keyphrases
  • low dose
  • coronavirus disease
  • sars cov
  • cardiovascular disease
  • high dose
  • early onset
  • type diabetes
  • respiratory syndrome coronavirus
  • cardiovascular events
  • drug induced
  • coronary artery disease
  • antiplatelet therapy